Sign In
Buy OTLK
$0.81
-0.0038 (-0.467%)
At Close: Jun 03, 2026
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
09:27am, Wednesday, 27'th Nov 2024
Outlook Therapeutics Inc. OTLK revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients.
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
06:50am, Wednesday, 27'th Nov 2024
ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom ea
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
08:05am, Wednesday, 06'th Nov 2024
Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outlook Therapeutics, Inc. (NASD
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
08:05am, Monday, 16'th Sep 2024
Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET Live video webcast with Russell Trenary, President and CEO of Outlook Thera
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
09:05am, Friday, 13'th Sep 2024
Webcast replay of fireside chat now available
Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
08:35am, Wednesday, 04'th Sep 2024
ISELIN, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom e
Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08:45am, Tuesday, 03'rd Sep 2024
ISELIN, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom e
Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles
04:11am, Monday, 26'th Aug 2024
Outlook Therapeutics faces liquidity issues and delays in FDA approval for its Wet AMD therapy, leading to a downgrade from Strong Buy to Buy. The potential blockbuster market for LYTENAVA in treating
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update
07:05am, Wednesday, 14'th Aug 2024
ISELIN, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized u
Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
09:05am, Monday, 12'th Aug 2024
ISELIN, N.J., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab
ISELIN, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that has achieved regulatory approval in the EU and UK for the first authorized u
Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024
09:10am, Tuesday, 30'th Jul 2024
Company to participate in a fireside chat on Monday, August 5 th at 8:00 AM ET
3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices
07:12am, Thursday, 11'th Jul 2024
Trading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps i
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
08:35am, Monday, 08'th Jul 2024
ISELIN, N.J., July 08, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab
